BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy

About this update from Biocryst Pharmaceuticals, Inc.

[{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world data demonstrating rapid, sustained reduction of patient-reported HAE attacks and consistently low attack rates among patients 12 years and older who started on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE), including patients who switched from other prophylactic therapies. The data are being presented at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), which is being conducted at the Kentucky International Convention Center in Louisville, Kentucky, from November 10-14, 2022. “These data are particularly exciting because, consistent with our long-term clinical program data, they show that patients on ORLADEYO sustain, and even improve, attack control the longer they are on therapy,” said Dr. Ryan Arnold, chief medical officer of BioCryst. “It is notable that this real-world evidence suggests that people living with HAE can maintain or improve control of their disease on ORLADEYO, regardless of prior treatment history,” Arnold added. “Every HAE patient has a unique experience with their therapy, and these data demonstrate that ORLADEYO can be a very effective treatment option for patients regardless of their reported prior attack rates or prophylactic therapy history. The sustained, long-term attack rate reductions we are seeing illustrate the durability of this efficacy for patients who are looking to improve control over their HAE by switching to a therapy with a less burdensome route of administration than subcutaneous or intravenous prophylactic therapies,” said William R. Lumry, M.D., clinical professor of internal medicine at the University of Texas Southwestern Medical School. BioCryst ACAAI 2022 Presentation Highlights The presentations at ACAAI are based on analyses from patient-reported results collected in the real-world clinical setting from BioCryst’s sole-source pharmacy, including HAE Type I and Type II patients in the United States who actively received ORLADEYO between December 16, 2020, and May 20, 2022. Consistently Low Hereditary Angioedema Attack Rates Observed with Berotralstat Regardless of Previous Prophylaxis: Real-World Outcomes (poster #P062); Saturday, Nove...

More updates from Biocryst Pharmaceuticals, Inc.